43.90
price up icon0.50%   0.22
after-market Handel nachbörslich: 43.90
loading
Schlusskurs vom Vortag:
$43.68
Offen:
$43.76
24-Stunden-Volumen:
840.68K
Relative Volume:
0.44
Marktkapitalisierung:
$4.67B
Einnahmen:
$761.41M
Nettoeinkommen (Verlust:
$98.16M
KGV:
53.66
EPS:
0.8181
Netto-Cashflow:
$141.79M
1W Leistung:
+4.85%
1M Leistung:
+36.55%
6M Leistung:
-42.85%
1J Leistung:
-36.92%
1-Tages-Spanne:
Value
$43.27
$44.42
1-Wochen-Bereich:
Value
$41.00
$44.42
52-Wochen-Spanne:
Value
$28.66
$91.00

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Firmenname
Corcept Therapeutics Inc
Name
Telefon
650.688.8803
Name
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Mitarbeiter
730
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-17
Name
Neueste SEC-Einreichungen
Name
CORT's Discussions on Twitter

Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
CORT icon
CORT
Corcept Therapeutics Inc
43.90 4.65B 761.41M 98.16M 141.79M 0.8181
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-03-26 Hochstufung Wolfe Research Underperform → Peer Perform
2025-12-31 Herabstufung Wolfe Research Peer Perform → Underperform
2025-12-16 Eingeleitet UBS Neutral
2025-11-18 Eingeleitet Wolfe Research Peer Perform
2023-11-06 Hochstufung Truist Hold → Buy
2023-04-11 Eingeleitet SVB Securities Market Perform
2023-04-04 Eingeleitet Piper Sandler Overweight
2023-02-15 Herabstufung Jefferies Buy → Hold
2022-08-01 Herabstufung Truist Buy → Hold
2022-07-27 Hochstufung Jefferies Hold → Buy
2022-06-27 Fortgesetzt Canaccord Genuity Buy
2022-02-02 Eingeleitet Canaccord Genuity Buy
2022-01-28 Eingeleitet Truist Buy
2020-08-05 Herabstufung Jefferies Buy → Hold
2019-09-24 Eingeleitet Jefferies Buy
2019-09-06 Eingeleitet H.C. Wainwright Buy
2019-02-04 Herabstufung B. Riley FBR Buy → Neutral
2018-08-10 Bestätigt Stifel Hold
2018-05-31 Herabstufung Stifel Buy → Hold
2018-03-09 Eingeleitet B. Riley FBR, Inc. Buy
2017-08-31 Eingeleitet Stifel Buy
2017-02-02 Eingeleitet Ladenburg Thalmann Buy
2015-04-21 Eingeleitet FBR Capital Outperform
2014-01-13 Herabstufung Stifel Buy → Hold
2013-08-09 Herabstufung Janney Buy → Neutral
2013-08-09 Herabstufung Ladenburg Thalmann Buy → Neutral
2012-02-21 Bestätigt JMP Securities Mkt Outperform
2010-01-06 Hochstufung Ladenburg Thalmann Neutral → Buy
2008-07-17 Eingeleitet Rodman & Renshaw Mkt Outperform
2007-06-21 Hochstufung Punk, Ziegel & Co Mkt Perform → Accumulate
Alle ansehen

Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten

pulisher
05:32 AM

CORT FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Corcept Therapeutics ... - Caledonian Record

05:32 AM
pulisher
12:41 PM

Deadline Alert: Corcept Therapeutics Incorporated (CORT) - GlobeNewswire

12:41 PM
pulisher
Apr 14, 2026

Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Apr 14, 2026
pulisher
Apr 14, 2026

CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept - GlobeNewswire

Apr 14, 2026
pulisher
Apr 14, 2026

CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - GlobeNewswire Inc.

Apr 14, 2026
pulisher
Apr 14, 2026

Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire

Apr 14, 2026
pulisher
Apr 14, 2026

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire

Apr 14, 2026
pulisher
Apr 14, 2026

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

Apr 14, 2026
pulisher
Apr 14, 2026

Pomerantz LLP Shares Class Action Details With Shareholders in Corcept Therapeutics Incorporated – CORT - ACCESS Newswire

Apr 14, 2026
pulisher
Apr 13, 2026

CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant Failure - The Malaysian Reserve

Apr 13, 2026
pulisher
Apr 13, 2026

Press releases provided by CNW - Techaeris

Apr 13, 2026
pulisher
Apr 13, 2026

Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK - MSN

Apr 13, 2026
pulisher
Apr 13, 2026

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - PR Newswire

Apr 13, 2026
pulisher
Apr 13, 2026

Corcept Leaders Sued Over Drug-Approval Remarks, Stock Sales - Bloomberg Law News

Apr 13, 2026
pulisher
Apr 13, 2026

Bragar Eagel & Squire, P.C. Reminds Investors that a Class - GlobeNewswire

Apr 13, 2026
pulisher
Apr 13, 2026

Corcept Therapeutics Incorporated Sued for Securities Law - GlobeNewswire

Apr 13, 2026
pulisher
Apr 13, 2026

CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire

Apr 13, 2026
pulisher
Apr 13, 2026

Corcept's Lifyorli Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer - National Today

Apr 13, 2026
pulisher
Apr 13, 2026

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Apr 13, 2026
pulisher
Apr 12, 2026

How The Corcept Therapeutics (CORT) Investment Story Is Shifting After Legal And Regulatory Updates - Yahoo Finance

Apr 12, 2026
pulisher
Apr 11, 2026

Corcept’s Lifyorli shows 35% reduction in death risk for ovarian cancer - Investing.com Australia

Apr 11, 2026
pulisher
Apr 11, 2026

DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - NewMediaWire

Apr 11, 2026
pulisher
Apr 11, 2026

FinancialContentDEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Deadline is April 21, 2026 - FinancialContent

Apr 11, 2026
pulisher
Apr 10, 2026

Corcept Therapeutics (CORT) Unveils Promising Survival Data from ROSELLA Trial - GuruFocus

Apr 10, 2026
pulisher
Apr 10, 2026

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Apr 10, 2026
pulisher
Apr 10, 2026

1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds - Yahoo Finance

Apr 10, 2026
pulisher
Apr 10, 2026

INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors - GlobeNewswire

Apr 10, 2026
pulisher
Apr 10, 2026

Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire

Apr 10, 2026
pulisher
Apr 10, 2026

CORT Shareholder Alert: Corcept Therapeutics Incorporated Securities Class Action Lawsuit ... - Bluefield Daily Telegraph

Apr 10, 2026
pulisher
Apr 10, 2026

CORT Shareholder Alert: Corcept Therapeutics Incorporated - GlobeNewswire

Apr 10, 2026
pulisher
Apr 10, 2026

Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT)Contact Kaplan Fox Before April 21, 2026 - FinancialContent

Apr 10, 2026
pulisher
Apr 10, 2026

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Corcept Therapeutics (CORT) - The Globe and Mail

Apr 10, 2026
pulisher
Apr 10, 2026

CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill

Apr 10, 2026
pulisher
Apr 09, 2026

Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire

Apr 09, 2026
pulisher
Apr 09, 2026

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire

Apr 09, 2026
pulisher
Apr 09, 2026

CORT DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026 - NewMediaWire

Apr 09, 2026
pulisher
Apr 09, 2026

CORT Investors Have Opportunity to Lead Corcept - GlobeNewswire

Apr 09, 2026
pulisher
Apr 09, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire

Apr 09, 2026
pulisher
Apr 08, 2026

Corcept therapeutics officer Guyer sells $819k in shares By Investing.com - Investing.com UK

Apr 08, 2026
pulisher
Apr 08, 2026

Corcept (NASDAQ: CORT) CDO sells 20,000 shares after option exercise - Stock Titan

Apr 08, 2026
pulisher
Apr 08, 2026

Corcept (CORT) director Wilson reports 5,000-share stock gift via trust - Stock Titan

Apr 08, 2026
pulisher
Apr 08, 2026

CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Inve - The National Law Review

Apr 08, 2026
pulisher
Apr 08, 2026

CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire

Apr 08, 2026
pulisher
Apr 08, 2026

CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 08, 2026
pulisher
Apr 08, 2026

CORT INVESTOR ALERT: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before Lead Plaintiff Deadline on April 21, 2026 - FinancialContent

Apr 08, 2026
pulisher
Apr 08, 2026

Corcept Therapeutics Inc (NASDAQ:CORT): An Affordable Growth Stock Built on a Strong Foundation - ChartMill

Apr 08, 2026
pulisher
Apr 07, 2026

Corcept Therapeutics Incorporated Securities Fraud Class - GlobeNewswire

Apr 07, 2026
pulisher
Apr 07, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill

Apr 07, 2026
pulisher
Apr 07, 2026

Corcept (CORT) Class Action Alleges Misstatements on FDA Data ConcernsHagens Berman - ChartMill

Apr 07, 2026
pulisher
Apr 07, 2026

Insider sells 20,000 CORT shares after option exercise (CORT) - Stock Titan

Apr 07, 2026
pulisher
Apr 07, 2026

CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 07, 2026

Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
Kapitalisierung:     |  Volumen (24h):